Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis

  • Kelly Claire Simon
  • , Eilis J. O'Reilly
  • , Kassandra L. Munger
  • , Susan Finerty
  • , Andrew J. Morgan
  • , Alberto Ascherio

Research output: Contribution to journalArticlepeer-review

Abstract

Previous infection with Epstein-Barr virus (EBV) and infectious mononucleosis are established multiple sclerosis (MS) risk factors, and elevated serum titers of anti-EBV nuclear antigen (anti-EBNA) antibodies in healthy adults are strongly correlated with future MS risk. In this prospective study, we investigated the association between EBV neutralizing antibodies and MS risk. MS risk tended to be higher in individuals with high titers of neutralizing antibodies compared to those with low titers (relative risk [RR] = 2.2, 95% confidence interval [CI] 0.97-5.1). This association was attenuated after adjustment for anti-EBNA1 IgG Ab titers (RR = 1.4, 95% CI 0.5-3.5). This preliminary finding warrants further study in a larger population.

Original languageEnglish
Pages (from-to)1185-1187
Number of pages3
JournalMultiple Sclerosis Journal
Volume18
Issue number8
DOIs
Publication statusPublished - Aug 2012
Externally publishedYes

Keywords

  • Epstein-Barr nuclear antigen
  • Epstein-Barr virus
  • glycoprotein 350
  • infectious mononucleosis
  • multiple sclerosis
  • neutralizing antibodies

Fingerprint

Dive into the research topics of 'Epstein-Barr virus neutralizing antibody levels and risk of multiple sclerosis'. Together they form a unique fingerprint.

Cite this